Close Menu

NEW YORK – Incyte received US Food and Drug Administration's approval for pemigatinib (Pemazyre) on Friday for previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.

Cholangiocarcinoma is a rare cancer of the bile ducts that occurs in approximately 8,000 patients in the US annually. FGFR2 fusions and rearrangements occur in between 9 percent and 14 percent of cholangiocarcinoma patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.